

### 2022 PORTFOLIO MOMENTUM

- Broadview’s portfolio companies have touched the lives of more than 380,000 patients to date
- The pipeline remains robust with more than 600 investment opportunities considered in 2022
- Our portfolio companies raised \$134M in co-investments, follow-on financings, and grants
- Our co-investors in 2022 included: Ajax Health, Aperture Venture Partners, BayMed Venture Partners, Boreal Ventures, Cleveland Clinic Ventures, Epidarex Capital, Grant Park Ventures, Hatteras Venture Partners, Laerdal Million Lives Fund, Vensana Capital, and multiple strategic investors
- Exit: NIDO Surgical was acquired by an undisclosed medical device company to further advance NIDO’s epicardial ablation technology

### NEW INVESTMENTS

- **Puzzle Medical**—percutaneous heart pump for patients with advanced heart failure
- **Nyra Medical**—transcatheter implant to treat mitral valve regurgitation
- **Cardiosense**—noninvasive sensors and algorithms for heart failure management



Longview Ventures is dedicated to making follow-on investments in select Broadview portfolio companies, with a focus on clinical-stage companies, Series B—Series C, as a complement to Broadview’s continued dedication to Seed and Series A financings.


### INVESTMENTS

- AtaCor Series B-1 to continue development of the Company’s extracardiac pacing system and to complete a 90-day ICD study
- Aria CV financing to continue clinical development of its counterpulsation system for PAH

### EXITS


Renovacor (NYSE: RCOR) was acquired by Rocket Pharma (NASDAQ: RCKT) to continue the development of Renovacor’s AAV-based gene therapy for BAG3-associated dilated cardiomyopathy.

**INVESTMENT DOLLARS LEVERAGED**



\*CO-AND FOLLOW-ON INVESTMENTS, AND NON-DILUTIVE GRANT FUNDING

**INVESTMENTS BY INDICATION**



Our mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

## TALENT

**Michael Mendelsohn, MD**, joined Broadview's Strategic Advisory Board. Dr. Mendelsohn is an internationally recognized cardiovascular physician-scientist who previously was Global Head of Cardiovascular Diseases at Merck and Chief Scientific Officer at Tufts Medical Center. He is currently the Founder and Chairman of the Board of Cardurion Pharmaceuticals.

**Maria Berkman, MD** was promoted to Managing Director of Longview Ventures. In her expanded role, Maria will focus on Longview Ventures strategy and evolution, working closely with the Leducq Trust and Longview Investment Advisory Committee to drive success and impact across the Longview portfolio; she will also continue in her role as Head of MedTech at Broadview.

**Khushbu Modi** joined the Broadview investment team as an Executive Assistant. Most recently, Khushbu worked in the corporate wellness industry where she was responsible for directing operations for multiple businesses while also serving as a coach and mentor.

## INVESTMENTS THROUGH 2022

Company	Technology/Therapy	Founders/Management
<b>2022</b>		
Puzzle Medical	<i>percutaneous heart pump for patients with advanced HF</i>	Jade Doucet-Martineau, Gabriel Georges, Francois Trudeau
Nyra Medical	<i>transcatheter implant to treat mitral valve regurgitation</i>	Murali Padala, Eric Sarin
Cardiosense	<i>noninvasive sensors and algorithms for heart failure management</i>	Amit Gupta, Omer Inan, Mozziyar Etemadi, Andrew Carek
<b>2021</b>		
XII Medical	<i>minimally-invasive technology to address obstructive sleep apnea</i>	Garrett Schwab, Anthony Caparso
RapidPulse	<i>aspiration system to treat acute ischemic stroke</i>	Sean McBrayer, David Gill, Carlos Rivera
Comanche BioPharma	<i>siRNA therapeutic for the treatment of preeclampsia</i>	T. Scott Johnson, Mike Young, Craig Mello
<b>2020</b>		
Antag Therapeutics	<i>GIPR antagonist for postural orthostatic tachycardia syndrome</i>	Alexander Sparre-Ulrich, Mette Rosenkilde, Jens Juul Holst
Basking Biosciences	<i>reversible anti-vWF aptamer for acute ischemic stroke</i>	Richard Shea, Shahid Nimjee, Bruce Sullenger
HAYA Therapeutics	<i>ncRNA-targeting antifibrotic therapeutics for heart failure</i>	Samir Ounzain, Daniel Blessing
<b>2019</b>		
Alleviant Medical	<i>atrial shunt for the treatment of heart failure</i>	Jacob Kriegel, Adam Berman, Mary Byron
Renovacor*	<i>gene therapy for a rare, familial form of dilated cardiomyopathy</i>	Maggie Cook, Arthur Feldman
CroiValve	<i>percutaneously implanted device for tricuspid regurgitation</i>	Lucy O'Keeffe, Martin Quinn
<b>2018</b>		
AtaCor Medical	<i>leadless extravascular pacing and defibrillation system</i>	Rick Sanghera, Sean McGeehan, Alan Marcovecchio
Kantum Pharma	<i>P2Y14 antagonists to ameliorate and prevent sterile inflammation</i>	Sylvie Breton, Glenn Batchelder
<b>2017</b>		
NIDO Surgical*	<i>device for epicardial ablation of ventricular tachycardia</i>	Pedro del Nido, Nikolay Vasilyev, Thomas Marchand
Mellitus	<i>novel biomarker for the screening and diagnosis of gestational diabetes</i>	Jose Halperin, Michael Chorev, John Tagliamonte
Adient*	<i>bioresorbable IVC filter for prevention of pulmonary embolism</i>	Mitch Eggers, Joseph Steele
Vectorious	<i>direct left atrial pressure sensor</i>	Oren Goldshtein, Eyal Orion
EP Sciences	<i>novel defibrillation waveform to reduce pain associated with ICD therapies</i>	Ron Berger, Howard Levin

\* Exited

## INVESTMENTS THROUGH 2022

Company	Technology/Therapy	Founders/Management
<b>2016</b>		
FineHeart	fully implantable, miniaturized circulatory support device for HF	Arnaud Mascarell, Stephane Garrigue, Jean-Luc Boulnois
Gila Therapeutics	PYY agonist for management and treatment of obesity	Tom Vasicek, Scott Schorer
Aeromics	small molecule for stroke-related cerebral edema	Tom Zindrick, Trevor Thompson
<b>2015</b>		
Pulmokine*	small molecule for pulmonary artery hypertension	Larry Zisman, Shreefal Mehta
Lyra Therapeutics*	bioresorbable platform for multiple indications	Bob Langer, George Whitesides, Maria Palasis
Epirium (Cardero)	mitochondrial biogenesis platform technology	George Schreiner, Sundeep Dugar, Russell Cox
<b>2014</b>		
ZZ Biotech	peptide therapeutic for stroke	Berislav Zlokovic, Kent Pryor, Joseph Romano
Ischemia Care	gene-based diagnostic for stroke	Jeff June
Acesion Pharma	small molecule therapeutic for AF	Ulrik Sørensen, Morten Grunnet, Jørgen Søbørg Petersen
Aria CV	device for pulmonary hypertension	John Scandurra, Karl Vollmers, Dan Gladney
<b>2013</b>		
Zumbro Discovery	peptide therapeutic for treatment of resistant hypertension	John Burnett, Horng Chen
BioKier	small molecule anti-diabetic treatment	George Szewczyk, Roger Nolan
Remedy*	small molecule for the treatment of central nervous system edema	Sven Jacobson
GI Windows*	non-surgical approach to gastric bypass	Chris Thompson, Marvin Ryou
<b>2012</b>		
VGS	external support for saphenous vein grafts in CABG	Eyal Orion, Steven Motes
InfoBionic	cloud-based remote arrhythmia monitoring	Jeremy Ruskin, Stuart Long
Herantis*	VEGF based gene therapy for lymphedema	Craig Cook
Declimmune	MAb for treatment of post MI and I/R injury	Christopher Mirabelli, Walter Newman
<b>2011</b>		
Cardialen	implantable cardioversion for the treatment of AF	Igor Efimov, Jeff Peters
NuPulse	counterpulsation device for the treatment of HF	Valluvan Jeevanandam, Douglas Altschuler, Sonna Patel-Raman
Aggamin	sFlt-1 apheresis treatment for preeclampsia	Ravi Thadhani, Paul Kussie, Ananth Karumanchi
Provasculon*	peptide therapeutics for treatment of MI and I/R injury	Rich Lee, Roger Kitterman
Apama*	novel ablation system for treatment of AF	Amr Salahieh
<b>2010</b>		
Allosteros	CaMKII inhibitors for HF and AF	Howard Schulman, Mark Anderson
Intravascular Imaging	NIRF device for intracoronary artery imaging	Farouc Jaffer, Vasilis Ntziachristos
Capricor*	allogeneic stem cell therapy after MI	Eduardo and Linda Marbán
CellAegis	remote ischemic conditioning for MI	Andrew Redington, Chris Calderone
<b>2009</b>		
CardiAQ Valve*	transcatheter mitral valve	Brent Ratz, Arshad Quadri, Rob Michiels
VentriNova	gene therapy for regeneration of cardiac tissue	Hina Chaudhry
miRagen*	microRNAs for cardiovascular and oncology indications	Bruce Booth, Mike Bristow, Eric Olson

\* Exited



## MANAGEMENT

Christopher Colecchi  
*Managing Director*

Maria Berkman, MD  
Christopher de Souza, PhD  
Daniel Gottlieb  
Benjamin Kreitman  
Hewmun Lau  
David Milan, MD  
Khushbu Modi  
Nichole Neal  
Tom Needham  
David Prim, PhD

## STRATEGIC ADVISORY BOARD

Eugene Braunwald, MD  
Thomas Hughes, PhD  
Costantino Iadecola, PhD  
Jerry Karabelas, PhD  
Martín Landaluce  
Joseph Loscalzo, MD, PhD  
Michael Mendelsohn, MD  
Eric Rose, MD  
David Tancredi, MD, PhD  
Hugh Watkins, MD, PhD

## ADVISORS

Annabel Chen-Tournoux, MD  
Teo Dagi, MD  
Marc Semigran, MD  
Viviany Taqueti, MD, MPH  
Sunny Varshney, MD



## MANAGEMENT

Maria Berkman, MD  
*Managing Director*

Christopher de Souza, PhD  
Daniel Gottlieb  
Benjamin Kreitman  
Hewmun Lau  
David Milan, MD  
Khushbu Modi  
Nichole Neal  
Tom Needham  
David Prim, PhD

## INVESTMENT ADVISORY COMMITTEE

### External Members

Terry McGuire  
Chris Mirabelli, PhD  
Eric Rose, MD

### Leducq Members

Martín Landaluce  
David Milan, MD  
David Tancredi, MD, PhD